These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1173 related articles for article (PubMed ID: 4803701)

  • 1. The measurement and manipulation of hemolytic complement levels in tumor bearing C57BL/6 mice.
    Drake WP; Ungaro PC; Mardiney MR
    Biomedicine; 1973 Jul; 18(4):284-9. PubMed ID: 4803701
    [No Abstract]   [Full Text] [Related]  

  • 2. Parameters of serum complement in relation to tumor therapy.
    Drake WP; Mardiney MR
    Biomedicine; 1974 May; 21(5):206-9. PubMed ID: 4433667
    [No Abstract]   [Full Text] [Related]  

  • 3. Protection against radiation leukemogenesis by repeated injections of immune and nonimmune foreign sera.
    Ferrer JF; Lieberman M; Kaplan HS
    Cancer Res; 1973 Jun; 33(6):1339-43. PubMed ID: 4352370
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of tumor and histocompatibility antigens in sera of lymphoma-bearing mice.
    Fujimoto S; Chen CH; Sabbadini E; Sehon AH
    J Immunol; 1973 Oct; 111(4):1093-100. PubMed ID: 4728678
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of antisera from histoincompatible mice on electrophoretic mobility of EL4 tumor cells.
    Wein J; Tanaka KK; Roberts E
    Cancer Res; 1967 Jun; 27(6):1066-72. PubMed ID: 4165265
    [No Abstract]   [Full Text] [Related]  

  • 6. Passive administration of antiserum and complement in producing anti-EL4 cytotoxic activity in the serum of C57BL-6 mice.
    Drake WP; Ungaro PC; Mardiney MR
    J Natl Cancer Inst; 1973 Apr; 50(4):909-14. PubMed ID: 4574188
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological stimulation with modified lymphoma cells in a minimally responsive tumor-host system.
    Prager MD; Baechtel FS; Ribble RJ; Ludden CM; Mehta JM
    Cancer Res; 1974 Dec; 34(12):3203-9. PubMed ID: 4429949
    [No Abstract]   [Full Text] [Related]  

  • 8. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 9. Complement activity of the serums of inbred strains of rats during egg-white shock.
    Ecker EE; Brenner LJ
    Z Immunitatsforsch Allerg Klin Immunol; 1966 Feb; 130(2):215-27. PubMed ID: 4231553
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of transplantable murine "L-1210" leukemia growth with hemi-and allogeneic immune sera.
    Schneiberg K; Rytwiński K; Bartnikowa W
    Pol Med Sci Hist Bull (1973); 1973; 15(6):589-96. PubMed ID: 4792408
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on mouse complement.
    Goto S; Fujii G; Ishibashi Y
    Jpn J Exp Med; 1971 Aug; 41(4):311-22. PubMed ID: 5315157
    [No Abstract]   [Full Text] [Related]  

  • 12. The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins.
    Sandberg AL; Osler AG; Shin HS; Oliveira B
    J Immunol; 1970 Feb; 104(2):329-34. PubMed ID: 4189670
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune hemolysis: serial studies of the dissociability of IgG and IgM anti-Forssman antibodies using the C'la fixation and transfer technique.
    Linscott WD
    J Immunol; 1969 Apr; 102(4):986-92. PubMed ID: 5768199
    [No Abstract]   [Full Text] [Related]  

  • 14. The kinetics of the interaction of heterologous anti-tumor serum and heterologous complement in non-tumor bearing mice.
    Drake WP; Roberts GC; Pendergrast WJ; Mardiney MR
    Biomedicine; 1975 Nov; 22(6):502-8. PubMed ID: 1225381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of binding from complete activation by use of heterologous components of complement.
    Koethe SM; Austen KF; Gigli I
    J Immunol; 1972 Apr; 108(4):1063-72. PubMed ID: 5023166
    [No Abstract]   [Full Text] [Related]  

  • 16. [6th symposium: Complement].
    Arerugi; 1970 Feb; 19(2):137-59. PubMed ID: 5421148
    [No Abstract]   [Full Text] [Related]  

  • 17. The combined effect of drugs and tumor-specific antibodies in protection against a mouse lymphoma.
    Davies DA
    Cancer Res; 1974 Nov; 34(11):3040-3. PubMed ID: 4418406
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies.
    Frank MM; Gaither T
    Immunology; 1970 Dec; 19(6):967-74. PubMed ID: 5487543
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of C. parvum on the effectiveness of passive serotherapy in the control of the EL4 lymphoma in C57BL/6 mice.
    O'Neill GJ; Stebbing N
    Br J Cancer; 1980 Feb; 41(2):243-9. PubMed ID: 7370164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncogenicity of simian adenovirus SA7(C8) for mice and rats].
    Tsetlin EM; Levenbuk IS; Al'tshtein AD
    Vopr Onkol; 1972; 18(9):37-42. PubMed ID: 4663691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.